Analysts’ Weekly Ratings Updates for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $219.00 price target on the stock, up previously from $147.00.
• 12/8/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Jazz Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Jazz Pharmaceuticals had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $188.00 price target on the stock, up previously from $163.00.
• 11/24/2025 – Jazz Pharmaceuticals had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $188.00 price target on the stock, up previously from $163.00.
• 11/18/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an “outperform” rating on the stock.
• 11/18/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $230.00 to $247.00. They now have a “buy” rating on the stock.
• 11/17/2025 – Jazz Pharmaceuticals was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 11/17/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $185.00 to $205.00. They now have an “overweight” rating on the stock.
• 11/8/2025 – Jazz Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating.
• 11/6/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $151.00 to $155.00. They now have an “outperform” rating on the stock.
• 10/27/2025 – Jazz Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $204.00 to $199.00. They now have an “overweight” rating on the stock.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Rick E. Winningham sold 5,500 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total value of $994,730.00. Following the sale, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. The trade was a 38.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $177.78, for a total value of $607,118.70. Following the completion of the sale, the director owned 20,449 shares in the company, valued at $3,635,423.22. This represents a 14.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 129,291 shares of company stock valued at $22,745,410 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.